Led by Dr Rodney Luwor, our brain cancer program is focused on one of the most aggressive and complex forms of cancer — glioblastoma.
This devastating disease is currently incurable. Even with treatment, the average survival time after diagnosis is just 12–15 months. One of the key reasons glioblastoma is so resistant to therapy is its ability to suppress the immune system — essentially hiding from the very cells that should be attacking it.
What remains unclear is how these brain tumour cells block immune function, and more importantly, how we can stop them.
The team are investigating the molecular and cellular mechanisms that glioblastoma cells use to avoid immune detection. By uncovering these immune evasion strategies, we aim to identify new targets for therapy — ultimately developing treatments that reawaken the immune system and give patients a better chance at survival.
With your support, we’re working to bring clarity to this deeply complex cancer — and move closer to a future where brain cancer no longer carries such a devastating prognosis.
Group Leaders
- Professor George Kannourakis
- Dr Rod Luwor
Scientists
- Dr Farah Ahmady-Nield
- Dylan King
